Answers are grounded in this paper and cite their sources.
Background A quantitative measure for assessing transcription-replication decoupling between serum hepatitis B virus (HBV) RNA and HBV DNA in patients with chronic HBV infection is currently lacking, and the clinical significance of this phenomenon remains to be clarified. This study constructed an HBV RNA/DNA decoupling index (HDI) and systematically evaluated its clinical associations. Methods A single-centre cross-sectional design was adopted, and 1210 patients with chronic HBV infection were enrolled (370 untreated and 840 receiving nucleos( t )ide analogue [NAs] therapy). The HDI was calculated as log₁₀(HBV RNA) − log₁₀(HBV DNA). Patients were stratified by treatment status and disease stage. Spearman correlation, Kruskal-Wallis H test, and multivariate linear and logistic regressions were performed. Results HBV RNA and HBV DNA were strongly correlated in untreated patients ( rₛ = 0.866), whereas the association weakened markedly in treated patients ( rₛ = 0.593). The HDI was highest in the low-level viraemia group and rose with disease stage ( H = 376.619 , P < 0.001). In HCC prediction, models incorporating HBV DNA or the HDI both improved discrimination over demographic variables alone (AUCs 0.783 and 0.776 vs 0.757), with the HDI-containing model performing comparably to the DNA-containing model. Conclusions The HDI quantitatively characterises HBV transcription-replication decoupling and is independently associated with disease stage and HCC risk. It may serve as a complementary tool to existing HBV serological monitoring.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: